These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 33740057)

  • 1. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Grinsztejn B; Fogel JM; Piwowar-Manning E; Li M; Weng L; McCauley M; Cummings V; Ahmed S; Haines CD; Bushman LR; Petropoulos C; Persaud D; Adeyeye A; Kofron R; Rinehart A; St Clair M; Rooney JF; Pryluka D; Coelho L; Gaur A; Middelkoop K; Phanuphak N; Cohen MS; Hendrix CW; Anderson P; Hanscom B; Donnell D; Landovitz RJ; Eshleman SH
    J Infect Dis; 2021 Nov; 224(9):1581-1592. PubMed ID: 33740057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
    Landovitz RJ; Donnell D; Clement ME; Hanscom B; Cottle L; Coelho L; Cabello R; Chariyalertsak S; Dunne EF; Frank I; Gallardo-Cartagena JA; Gaur AH; Gonzales P; Tran HV; Hinojosa JC; Kallas EG; Kelley CF; Losso MH; Madruga JV; Middelkoop K; Phanuphak N; Santos B; Sued O; Valencia Huamaní J; Overton ET; Swaminathan S; Del Rio C; Gulick RM; Richardson P; Sullivan P; Piwowar-Manning E; Marzinke M; Hendrix C; Li M; Wang Z; Marrazzo J; Daar E; Asmelash A; Brown TT; Anderson P; Eshleman SH; Bryan M; Blanchette C; Lucas J; Psaros C; Safren S; Sugarman J; Scott H; Eron JJ; Fields SD; Sista ND; Gomez-Feliciano K; Jennings A; Kofron RM; Holtz TH; Shin K; Rooney JF; Smith KY; Spreen W; Margolis D; Rinehart A; Adeyeye A; Cohen MS; McCauley M; Grinsztejn B;
    N Engl J Med; 2021 Aug; 385(7):595-608. PubMed ID: 34379922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
    Marzinke MA; Fogel JM; Wang Z; Piwowar-Manning E; Kofron R; Moser A; Bhandari P; Gollings R; Bushman LR; Weng L; Halvas EK; Mellors J; Anderson PL; Persaud D; Hendrix CW; McCauley M; Rinehart AR; St Clair M; Ford SL; Rooney JF; Adeyeye A; Chariyalertsak S; Mayer K; Arduino RC; Cohen MS; Grinsztejn B; Hanscom B; Landovitz RJ; Eshleman SH
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0005323. PubMed ID: 36995219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
    Eshleman SH; Fogel JM; Piwowar-Manning E; Chau G; Cummings V; Agyei Y; Richardson P; Sullivan P; Haines CD; Bushman LR; Petropoulos C; Persaud D; Kofron R; Hendrix CW; Anderson PL; Farrior J; Mellors J; Adeyeye A; Rinehart A; St Clair M; Ford S; Rooney JF; Mathew CA; Hunidzarira P; Spooner E; Mpendo J; Nair G; Cohen MS; Hughes JP; Hosseinipour M; Hanscom B; Delany-Moretlwe S; Marzinke MA
    J Infect Dis; 2022 May; 225(10):1741-1749. PubMed ID: 35301540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
    Landovitz RJ; Hanscom BS; Clement ME; Tran HV; Kallas EG; Magnus M; Sued O; Sanchez J; Scott H; Eron JJ; Del Rio C; Fields SD; Marzinke MA; Eshleman SH; Donnell D; Spinelli MA; Kofron RM; Berman R; Piwowar-Manning EM; Richardson PA; Sullivan PA; Lucas JP; Anderson PL; Hendrix CW; Adeyeye A; Rooney JF; Rinehart AR; Cohen MS; McCauley M; Grinsztejn B;
    Lancet HIV; 2023 Dec; 10(12):e767-e778. PubMed ID: 37952550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Global HIV Incidence Analysis and Implications for Affordability Using Long-Acting Cabotegravir Versus Continuous and Event-Driven Oral Preexposure Prophylaxis.
    Sharma I; Hill A
    Clin Infect Dis; 2024 Feb; 78(2):386-394. PubMed ID: 37665213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Cabotegravir Long-Acting for HIV Pre-exposure Prophylaxis in the United States.
    Brogan AJ; Davis AE; Mellott CE; Fraysse J; Metzner AA; Oglesby AK
    Pharmacoeconomics; 2024 Apr; 42(4):447-461. PubMed ID: 38267806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
    Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
    J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
    Marzinke MA; Hanscom B; Wang Z; Safren SA; Psaros C; Donnell D; Richardson PA; Sullivan P; Eshleman SH; Jennings A; Feliciano KG; Jalil E; Coutinho C; Cardozo N; Maia B; Khan T; Singh Y; Middelkoop K; Franks J; Valencia J; Sanchez N; Lucas J; Rooney JF; Rinehart AR; Ford S; Adeyeye A; Cohen MS; McCauley M; Landovitz RJ; Grinsztejn B;
    Lancet HIV; 2023 Nov; 10(11):e703-e712. PubMed ID: 37783219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
    Landovitz RJ; Li S; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Hendrix CW; Eshleman SH; Zhang Y; Tolley E; Sugarman J; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Spreen WR; Cohen MS; McCauley M; Eron JJ
    PLoS Med; 2018 Nov; 15(11):e1002690. PubMed ID: 30408115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States : A Cost-Effectiveness Analysis.
    Neilan AM; Landovitz RJ; Le MH; Grinsztejn B; Freedberg KA; McCauley M; Wattananimitgul N; Cohen MS; Ciaranello AL; Clement ME; Reddy KP; Hyle EP; Paltiel AD; Walensky RP
    Ann Intern Med; 2022 Apr; 175(4):479-489. PubMed ID: 35099992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
    Delany-Moretlwe S; Hughes JP; Bock P; Ouma SG; Hunidzarira P; Kalonji D; Kayange N; Makhema J; Mandima P; Mathew C; Spooner E; Mpendo J; Mukwekwerere P; Mgodi N; Ntege PN; Nair G; Nakabiito C; Nuwagaba-Biribonwoha H; Panchia R; Singh N; Siziba B; Farrior J; Rose S; Anderson PL; Eshleman SH; Marzinke MA; Hendrix CW; Beigel-Orme S; Hosek S; Tolley E; Sista N; Adeyeye A; Rooney JF; Rinehart A; Spreen WR; Smith K; Hanscom B; Cohen MS; Hosseinipour MC;
    Lancet; 2022 May; 399(10337):1779-1789. PubMed ID: 35378077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative cost-effectiveness of long-acting injectable cabotegravir versus oral pre-exposure prophylaxis in South Africa based on the HPTN 083 and HPTN 084 trials: a modelled economic evaluation and threshold analysis.
    Jamieson L; Johnson LF; Nichols BE; Delany-Moretlwe S; Hosseinipour MC; Russell C; Meyer-Rath G
    Lancet HIV; 2022 Dec; 9(12):e857-e867. PubMed ID: 36356603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.
    Mitchell KM; Boily MC; Hanscom B; Moore M; Todd J; Paz-Bailey G; Wejnert C; Liu A; Donnell DJ; Grinsztejn B; Landovitz RJ; Dimitrov DT
    Lancet Reg Health Am; 2023 Feb; 18():100416. PubMed ID: 36844011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S
    JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabotegravir: The First Long-Acting Injectable for HIV Preexposure Prophylaxis.
    Durham SH; Milam A; Waer D; Chahine EB
    Ann Pharmacother; 2023 Mar; 57(3):306-316. PubMed ID: 35778802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
    Donnell D; Gao F; Hughes JP; Hanscom B; Corey L; Cohen MS; Edupuganti S; Mgodi N; Rees H; Baeten JM; Gray G; Bekker LG; Hosseinipour M; Delany-Moretlwe S
    J Int AIDS Soc; 2023 Jun; 26(6):e26118. PubMed ID: 37363917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population-level impact of expanding PrEP coverage by offering long-acting injectable PrEP to MSM in three high-resource settings: a model comparison analysis.
    Stansfield SE; Heitner J; Mitchell KM; Doyle CM; Milwid RM; Moore M; Donnell DJ; Hanscom B; Xia Y; Maheu-Giroux M; Vijver DV; Wang H; Barnabas R; Boily MC; Dimitrov DT
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26109. PubMed ID: 37439080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.
    Solomon MM; Mayer KH; Glidden DV; Liu AY; McMahan VM; Guanira JV; Chariyalertsak S; Fernandez T; Grant RM;
    Clin Infect Dis; 2014 Oct; 59(7):1020-6. PubMed ID: 24928295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.